Compare OCSL & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | RVPHW |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | N/A |
| IPO Year | 2008 | N/A |
| Metric | OCSL | RVPHW |
|---|---|---|
| Price | $13.64 | $0.01 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 596.7K | 22.4K |
| Earning Date | 11-18-2025 | 03-14-2025 |
| Dividend Yield | ★ 11.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $316,801,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.44 | $0.13 |
| 52 Week High | $16.50 | $0.15 |
| Indicator | OCSL | RVPHW |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 28.60 |
| Support Level | $13.51 | $0.01 |
| Resistance Level | $13.76 | $0.01 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 68.38 | 18.52 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.